Objective A safe and effective medication model was put forward through the treatment of a patient with Trousseau syndrome complicated with ovarian cancer by clinical pharmacist.Methods Clinical pharmacists participated in the treatment team to make individual treatment plan for Trousseau syndrome patients with ovarian cancer through consultation,clinical ward rounds,evidence-based medicine and discussion.Results The clinical pharmacist participated in the entire pharmaceutical care for the patients.They assisted the doctor to make individual anticoagulation and chemotherapy plan.The anticoagulation treatment was safe and effective,with no thromboembolism and hemorrhage.The chemotherapy process was smooth,with no adverse reaction occurred,and the patients condition improved,leading to discharged.Conclusion Clinical pharmacists participated in clinical evaluation of the feasibility of tumor chemotherapy plan,balanced the risk of patients with thrombosis and bleeding,formulated individualized anticoagulation treatment plan,and carried out pharmaceutical education and adverse reaction monitoring,which improved the efficacy and safety of medication in patients with ovarian cancer combined with multiple organ thromboembolism.

Objective A safe and effective medication model was put forward through the treatment of a patient with Trousseau syndrome complicated with ovarian cancer by clinical pharmacist.Methods Clinical pharmacists participated in the treatment team to make individual treatment plan for Trousseau syndrome patients with ovarian cancer through consultation,clinical ward rounds,evidence-based medicine and discussion.Results The clinical pharmacist participated in the entire pharmaceutical care for the patients.They assisted the doctor to make individual anticoagulation and chemotherapy plan.The anticoagulation treatment was safe and effective,with no thromboembolism and hemorrhage.The chemotherapy process was smooth,with no adverse reaction occurred,and the patients condition improved,leading to discharged.Conclusion Clinical pharmacists participated in clinical evaluation of the feasibility of tumor chemotherapy plan,balanced the risk of patients with thrombosis and bleeding,formulated individualized anticoagulation treatment plan,and carried out pharmaceutical education and adverse reaction monitoring,which improved the efficacy and safety of medication in patients with ovarian cancer combined with multiple organ thromboembolism.

Mechanical allodynia (MA), including punctate and dynamic forms, is a common and debilitating symptom suffered by millions of chronic pain patients. Some peripheral injuries result in the development of bilateral MA, while most injuries usually led to unilateral MA. To date, the control of such laterality remains poorly understood. Here, to study the role of microglia in the control of MA laterality, we used genetic strategies to deplete microglia and tested both dynamic and punctate forms of MA in mice. Surprisingly, the depletion of central microglia did not prevent the induction of bilateral dynamic and punctate MA. Moreover, in dorsal root ganglion-dorsal root-sagittal spinal cord slice preparations we recorded the low-threshold Aβ-fiber stimulation-evoked inputs and outputs of superficial dorsal horn neurons. Consistent with behavioral results, microglial depletion did not prevent the opening of bilateral gates for Aβ pathways in the superficial dorsal horn. This study challenges the role of microglia in the control of MA laterality in mice. Future studies are needed to further understand whether the role of microglia in the control of MA laterality is etiology-or species-specific.
Mice ; Animals ; Hyperalgesia/metabolism* ; Microglia/metabolism* ; Disease Models, Animal ; Spinal Cord/metabolism* ; Spinal Cord Dorsal Horn/metabolism* ; Ganglia, Spinal/metabolism*